KMT2A and cancer: Similar to MLL1 in pancreatic cancer, overexpression of MLL3 in prostate cancer can also activate PD-L1 expression via regulation of the PD-L1 enhancer region, suggesting its potentially vital role in overcoming immune evasion in cancer cells [179].